REGENERON PHARMACEUTICALS INC.

ISIN: US75886F1075 WKN: 75886F107 Asset Class: Stock

2024/05/30 21:59:52
Price
970.34

REGENERON

USD **Difference** 0.40%(3.85)

Contact Details

REGENERON
PHARMACEUTICALS INC

PHARMACEUTICALS INC.

777 Old Saw Mill River Road

777 Old Gaw Willi Parver Produc

10591-6707 Tarrytown


Tel: +1-914-847-7000

Fax: + Web:

http://www.regeneron.com

E-mail:

usinfo@regeneron.com



Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Financial figures, Fiscal year: from 01.01. to 31.12.

	2023		2022		2021	
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	19,479,200,000		15,884,100,000		14,014,900,000	
Common stock capital		100,000		100,000		100,000
Fixed assets	13,651,400,000		13,388,600,000		11,419,900,000	
Equity capital of a company		25,973,100,000		22,664,000,000		18,768,800,000
Cash and cash equivalents	2,730,000,000		3,105,900,000		2,885,600,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		3,423,400,000		3,141,300,000		3,932,500,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		3,734,100,000		3,467,400,000		2,733,500,000
Different income		-		-		-
Other liabilities		980,800,000		707,800,000		753,500,000
Total assets	33,130,600,000	33,130,600,000	29,272,700,000	29,272,700,000	25,434,800,000	25,434,800,000

Balance notes

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	13,450	11,851	10,368
Equity ratio	78.40%	77.42%	73.79%
Debt-equity ratio	27.56%	29.16%	35.52%

Others

	2023	2022	2021
Tax Expense Rate	5.85%	10.71%	13.41%

REGENERON PHARMACEUTICALS INC.

ISIN: **US75886F1075** WKN: **75886F107** Asset Class: **Stock**

Income statement			
	2023	2022	2021
Turnover	13,117,200,000	12,172,900,000	16,071,700,000
Net income	3,953,600,000	4,338,400,000	8,075,300,000
EBIT	3,481,840,800	4,386,968,200	8,651,218,200
Operating income before taxes	4,199,300,000	4,858,800,000	9,325,800,000
Cash Flow	4,594,000,000	5,014,900,000	7,081,300,000
Net interest income	422,900,000	100,700,000	-57,300,000
Research and development expenses	3,986,700,000	3,056,100,000	2,621,900,000
Income taxes	245,700,000	520,400,000	1,250,500,000
Result from investments in subsidaries, associates and other	0	-	-
Revenues per employee	899,186	947,044	1,429,216

Board of Directors

Members of Management Board		
George Yancopoulos	Chairman of Board of Directors	
Bonnie Bassler	Member of Board of Directors	
Craig Thompson	Member of Board of Directors	
David Schenkein	Member of Board of Directors	
Huda Zoghbi	Member of Board of Directors	
Joseph Goldstein	Member of Board of Directors	
Kathryn Guarini	Member of Board of Directors	
Michael Brown	Member of Board of Directors	
N. Coles	Member of Board of Directors	
Arthur Ryan	Member of Board of Directors	
Christine Poon	Member of Board of Directors	
George Sing	Member of Board of Directors	
Leonard S. Schleifer	Chairman of Managing Board	
George D. Yancopoulos	Member of Executive Committee	
Bob McCowan	Member of Executive Committee	
Joseph J. LaRosa	Member of Executive Committee	
Marion McCourt	Member of Executive Committee	
Melissa Lozner	Member of Executive Committee	
Robert E. Landry	Member of Executive Committee	
Sally A. Paull	Member of Executive Committee	
Smita Pillai	Member of Executive Committee	